Estrella Immunopharma (ESLA): Armistice Capital, LLC now owns 8.4% of ESLA as a passive investor 8.4%
Armistice Capital, LLC now owns 8.4% of ESLA as a passive investor.
- 8.4%
- Stake
- 3.67M
- Shares owned
- Stake as of
- Sep 30, 2026
- Filed
- Nov 16, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 17, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On August 17, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share for 30 consecutive business days from July 6, 2026 through August 14,…”
- Sep 1, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On September 1, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the market value of the Company’s listed securities (“MVLS”) was below $35,000,000 for 30 consecutive business days from July 21, 2026 through August 31, 2026, the Company no longer complies with…”
What came next
- Oct 25, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 25, 2026, the Board of Directors (the “Board”) of Estrella Immunopharma, Inc. (the “Company”) appointed Cynthia Pussinen, age 57, as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026.”
- Nov 16, 20265% stakeArmistice Capital, LLC reported a passive stake (13G) of 8.4%
How to read SEC Schedule 13G
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Estrella Immunopharma
For Estrella Immunopharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ESLA page.
How this filing works
Explore the data
Common questions
What does this filing report about Estrella Immunopharma (ESLA) stock?
Armistice Capital, LLC now owns 8.4% of ESLA as a passive investor. Of the company, Schedule 13G (passive).
When did it happen, and when was it made public?
Stake as of: Sep 30, 2026. Filed: Nov 16, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Estrella Immunopharma recently?
For Estrella Immunopharma, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the ESLA page.
Does this mean ESLA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Estrella Immunopharma
Everything OQRO holds on this company is on its ESLA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
